NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Aarti Drugs Q2 FY27 Concall: Record Revenue of Rs 829 Cr, Up 27% YoY; PAT Up 83%
Aarti Drugs released its Q2 FY27 earnings call transcript, highlighting its highest-ever quarterly consolidated revenue of Rs 829 crore (up 27% YoY) and a sharp 83% increase in PAT to Rs 83 crore. EBITDA margins expanded 370 bps YoY to 16.6%, driven by a 16% realization improvement and operational efficiencies from backward integration at its Saykha facility. The formulation business grew 58% YoY to Rs 130 crore, supported by a 73% surge in formulation exports. Capacity expansions across Sarigam, Tarapur, and Baddi are progressing to drive future growth.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the detailed Q2 & H1 FY27 earnings conference call transcript outlining operational performance, backward integration progress, and capex timelines.
ஏன் இது முக்கியம்Demonstrates structural margin recovery via internal backward integration (Saykha amines facility) alongside supportive industry-wide API pricing, aiding long-term operating leverage.
📅 குறுகிய காலம்Positive earnings sentiment supported by strong quarterly margin expansion and higher API realizations, though management noted order books run 1-3 months out.
📈 நீண்ட காலம்Structural integration via captive amine production and capacity additions at Sarigam, Tarapur, and Baddi position the company for higher share in regulated export markets.
⚠ அபாய எச்சரிக்கைகள்
Vulnerability of realization gains to normalization in global API pricing and geopolitical tailwinds
Execution delays in multi-site capex projects (Sarigam, Tarapur, and Baddi)
Raw material price volatility risk given typical 40-50 days inventory holding
👀 கவனிக்க வேண்டியவை
Track the commercialization timeline of the Sarigam metformin expansion in early FY28 and margin sustainability as elevated raw material and API realization dynamics normalize.
Aarti Drugs Subsidiary Receives 3 US FDA Form 483 Observations at Baddi Unit
The US FDA inspected the formulation manufacturing facility of Aarti Drugs' wholly owned subsidiary, Pinnacle Life Science Private Limited, located at Baddi, Himachal Pradesh, between November 2 and November 6, 2026. At the close of the audit, the regulator issued a Form 483 with 3 inspectional observations. Management highlighted that none of the observations are linked to data integrity, and there is no immediate impact on the company's financial or operational activities. The subsidiary plans to work with the US FDA to resolve the points raised.
உச்சம் நம்பிக்கை
என்ன மாறியதுUS FDA concluded an audit at Pinnacle Life Science's Baddi facility with 3 Form 483 observations.
ஏன் இது முக்கியம்Formulation exports to regulated markets like the US are critical for Aarti Drugs' long-term margins, though absence of data integrity issues lowers the severity risk.
Form 483 observations: 3Inspection start date: 2nd நவம்பர் 2026Inspection end date: 6th நவம்பர் 2026
📅 குறுகிய காலம்The stock may experience mild overhang until Aarti Drugs submits its corrective action plan (CAPA) and US FDA's final classification is communicated.
📈 நீண்ட காலம்A successful EIR resolution would support Aarti Drugs' strategy to expand formulation exports into developed markets.
⚠ அபாய எச்சரிக்கைகள்
Risk of escalation to Warning Letter or Import Alert if remediation is deemed insufficient by US FDA
👀 கவனிக்க வேண்டியவை
Track the subsidiary's response within the standard 15-day timeline and whether the US FDA issues an EIR (Establishment Inspection Report) or escalates to a Warning Letter/OAI status.
Aarti Drugs Q2 FY27 Net Profit Surges 83% YoY to ₹82.8 Cr, Revenue Up 27% to ₹828.8 Cr
Aarti Drugs reported robust Q2 FY27 performance with total revenue expanding 27% YoY to ₹828.8 crore and PAT surging 83% YoY to ₹82.8 crore. EBITDA jumped 63% YoY to ₹137.9 crore, with EBITDA margins reaching a multi-year high of 16.6% (up 370 bps YoY), supported by backward integration at its Sayakha facility. Formulations revenue grew 58% and Specialty Chemicals nearly doubled as domestic and export volumes scaled up. Additionally, the company announced a leadership transition effective October 1, 2026, with Rashesh Gogri taking over as Chairman following Prakash M. Patil's retirement.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarti Drugs achieved record quarterly revenue and EBITDA in Q2 FY27 along with a CEO and Chairman leadership transition effective October 1, 2026.
ஏன் இது முக்கியம்Demonstrates the operating leverage and margin recovery from the commissioned Sayakha amines facility, delivering on management's stated target of expanding EBITDA margins toward 15-16%.
Q2 FY27 Total Revenue: ₹828.8 கோடிQ2 FY27 EBITDA Margin: 16.6%Q2 FY27 PAT: ₹82.8 கோடிH1 FY27 Total Revenue: ₹1,532.4 கோடிH1 FY27 Cash from Operations: ₹65.7 கோடி
📅 குறுகிய காலம்Strong operational beat on revenue and margins is likely to be received positively by markets, highlighting margin inflection after several subdued quarters.
📈 நீண்ட காலம்Backward integration and expanding exposure to formulations and regulated-market capacities provide structural margin stability and growth visibility across the core API business.
⚠ அபாய எச்சரிக்கைகள்
Working capital expansion caused H1 FY27 operating cash flow to drop to ₹65.7 crore vs ₹152.4 crore in H1 FY26
Volatility in raw material prices and pricing pressure in key antibiotic therapies
👀 கவனிக்க வேண்டியவை
Track whether consolidated EBITDA margins sustain above 15-16% in subsequent quarters and monitor the commercialization timeline of USFDA-compliant capacity expansions at Tarapur, Sarigam, and Baddi.
Aarti Drugs Q2 FY27 PAT Jumps 83% YoY to ₹82.8 Cr; EBITDA Margin Expands to 16.6%
Aarti Drugs reported a strong Q2 FY27 performance with consolidated revenue growing 27% YoY to ₹828.8 crore and EBITDA surging 63% YoY to ₹137.9 crore. PAT expanded 83% YoY to ₹82.8 crore, driven by robust volume growth and backward integration benefits from the Sayakha facility. EBITDA margins expanded 370 bps YoY to 16.6%, reaching multi-year highs. Formulations saw 58% YoY revenue growth, while Specialty Chemicals grew 92% YoY.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarti Drugs posted highest-ever quarterly EBITDA and revenue, reflecting a sharp profitability turnaround driven by backward integration and volume expansion.
ஏன் இது முக்கியம்The jump in EBITDA margin to 16.6% aligns with management's strategic goal of achieving 15-16% sequential margins, confirming cost savings from in-house Metformin intermediate production.
Consolidated Revenue Q2 FY27: ₹828.8 கோடிConsolidated PAT Q2 FY27: ₹82.8 கோடிEBITDA Margin Q2 FY27: 16.6%Q2 FY27 PAT vs TTM PAT: ~43.4%
📅 குறுகிய காலம்Strong operational beat and sharp margin improvement are likely to be received positively by the market in the immediate trading sessions.
📈 நீண்ட காலம்Backward integration at the Sayakha facility and ongoing expansions targeting regulated markets position the company for sustainable double-digit growth and structural margin resilience.
Exposure to raw material price volatility and geopolitical supply chain disruptions
👀 கவனிக்க வேண்டியவை
Track the ramp-up and margin sustainability of backward integration at the Sayakha amines plant, along with progress on USFDA-compliant capacity expansions at Tarapur, Sarigam, and Baddi.
Aarti Drugs: Adhish Patil Appointed MD as Chairman Prakash Patil Retires
Aarti Drugs has announced key executive leadership changes effective close of business September 30, 2026. Founder-promoter Shri Prakash M. Patil has ceased to be Chairman, MD, and CEO due to early retirement. Concurrently, CFO Shri Adhish P. Patil has been elevated to the role of Managing Director effective October 1, 2026, following shareholder approval at the AGM on September 26, 2026. A replacement CFO will be appointed in due course while Adhish Patil continues oversight in the interim.
உச்சம் நம்பிக்கை
என்ன மாறியதுPrakash M. Patil retired from Chairman/MD/CEO roles; former CFO Adhish P. Patil took over as Managing Director.
ஏன் இது முக்கியம்Represents a planned generational leadership transition in a Rs 3,944 Cr bulk drugs manufacturer delivering Rs 2,604 Cr in TTM revenue.
Effective Date of Transition: செப்டம்பர் 30, 2026MD Appointment Date: அக்டோபர் 1, 2026AGM Approval Date: செப்டம்பர் 26, 2026
📅 குறுகிய காலம்Neutral market impact expected as this formalizes the leadership transition previously intimated on July 31, 2026.
📈 நீண்ட காலம்Provides succession clarity and continuity since the former CFO steps into the MD role to drive margin recovery and backward integration initiatives.
⚠ அபாய எச்சரிக்கைகள்
Vacant CFO position pending permanent appointment
Key person transition risks during strategic capacity ramp-ups
👀 கவனிக்க வேண்டியவை
Track the upcoming appointment of the new Chief Financial Officer and monitor any shifts in capital allocation or growth strategies during the next quarterly earnings call.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Aarti Drugs Appoints CFO Adhish Patil as MD Effective October 1, 2026; Rejigs Board
Shareholders of Aarti Drugs approved key leadership changes at the 41st AGM held on September 26, 2026. Chief Financial Officer Adhish Prakash Patil has been appointed as Managing Director effective October 1, 2026, succeeding Prakash M. Patil who opted for early retirement ahead of his term ending May 31, 2027. Additionally, Nilesh Bhalchandra Patil was appointed as Whole-time Director for 5 years replacing retiring director Uday Moreshwar Patil. Multiple directors, including Joint MD Harshit M. Savla, also secured re-appointments starting 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal shareholder approval of succession planning: CFO Adhish Prakash Patil takes over as Managing Director on October 1, 2026, as Prakash M. Patil steps down early.
ஏன் இது முக்கியம்Represents a planned generational transition in executive leadership for a company generating ₹2,604 Cr in TTM revenue, ensuring management continuity while bringing long-tenured internal leadership to the helm.
MD Appointment Effective Date: அக்டோபர் 01, 2026Outgoing MD Original Term End: மே 31, 2027Whole-time Director Appointment Term: 5 yearsIncoming MD Experience: 21 years
📅 குறுகிய காலம்Neutral reaction expected as the succession involves an internal leader (CFO since April 2014) and ensures operational continuity.
📈 நீண்ட காலம்Ensures smooth leadership handover from the promoter generation to drive key strategic targets, including GLP-1 API entry and EBITDA margin expansion back toward 15-16%.
⚠ அபாய எச்சரிக்கைகள்
Key person transition
Vacancy created in the Chief Financial Officer (CFO) role
👀 கவனிக்க வேண்டியவை
Track the upcoming Q2 FY27 earnings for strategic commentary under the new MD and watch for the announcement of a successor for the CFO role vacated by Adhish Patil.
Supreme Court Dismisses ₹230.70 Cr GST Demand Case Against Aarti Drugs
The Supreme Court of India has dismissed a Special Leave Petition (SLP) filed by the GST Department against Aarti Drugs, concluding a long-standing tax dispute. The case originated from a show-cause notice proposing a demand of ₹230.70 Crores for the period FY 2017-18 to FY 2021-22. Following a favorable ruling from the Bombay High Court which set aside the demand, the Supreme Court's dismissal of the department's appeal provides finality to the matter. This resolution removes a significant contingent liability that was equivalent to approximately 120% of the company's TTM Net Profit.
உச்சம் நம்பிக்கை
என்ன மாறியதுA major tax litigation involving a potential ₹230.70 Crore liability has been permanently resolved in the company's favor following the Supreme Court's dismissal of the GST Department's appeal.
ஏன் இது முக்கியம்The resolution eliminates a significant financial risk; the disputed amount was larger than the company's entire annual profit (TTM PAT of ₹192 Cr), which could have severely impacted cash flows if ruled otherwise.
Total Disputed Amount: ₹230.70 கோடிDisputed Amount vs TTM PAT: 120.1%Disputed Amount vs Net Worth: 16.4%Specific Penalty Set Aside: ₹20.72 கோடிPeriod of Dispute: FY 2017-18 to FY 2021-22
📅 குறுகிய காலம்Positive sentiment is expected as the company successfully defended a material tax claim, ensuring no unexpected cash outflows in the near term.
📈 நீண்ட காலம்Structural positive as it clears the contingent liability profile, allowing management to focus on its backward integration and Greenfield expansion projects.
👀 கவனிக்க வேண்டியவை
Investors should note the removal of this legal overhang from the balance sheet. Focus can now return to the company's 15% growth strategy and the ramp-up of the Sayakha amines facility.
Aarti Drugs reported a strong start to FY27 with consolidated revenue growing 19% YoY to ₹703.6 crore. EBITDA margins expanded by 120 bps to 13.8%, driven by improved API realizations and volume growth despite higher freight costs. The strategic Sayakha facility reached 65% utilization and is expected to meet 80-90% of captive intermediate requirements by Q3 FY27. Additionally, the company is doubling its oral solid dosage capacity at Baddi to scale its formulation exports, which already account for 74% of segment revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully stabilized operations at its new Sayakha plant and is transitioning from external intermediate procurement to captive production.
ஏன் இது முக்கியம்Backward integration through Sayakha is expected to add ~1% to gross margins at peak, while doubling formulation capacity targets higher-margin regulated export markets.
Q1 FY27 Revenue: ₹703.6 கோடிRevenue vs TTM Revenue: 28.2%EBITDA லாப வரம்பு: 13.8%Sayakha Utilization: 65%Formulation Export Share: 74%Adjusted PAT Growth: 29%
📅 குறுகிய காலம்The stock may see positive sentiment following the margin expansion and the clear roadmap for backward integration benefits in the coming quarters.
📈 நீண்ட காலம்Structural improvements through capacity doubling in formulations and cost leadership via backward integration could lead to a sustainable re-rating of the business.
⚠ அபாய எச்சரிக்கைகள்
Volatility in raw material prices (specifically ammonia derivatives)
Elevated international freight costs
Geopolitical risks impacting West Asian trade routes
👀 கவனிக்க வேண்டியவை
Monitor the EBITDA margin trajectory toward the management's 15-16% target as Sayakha utilization ramps up. Watch for the completion timeline of the Baddi expansion and any new USFDA/EDQM approvals for regulated market entry.
Aarti Drugs Q1 FY27: 19% Revenue Growth to ₹703.6 Cr; EBITDA Margins Expand to 13.8%
Aarti Drugs reported a strong operational start to FY27 with consolidated revenue growing 19% YoY to ₹703.6 Cr, driven by volume growth and a recovery in the pricing environment. EBITDA increased 30% YoY to ₹96.9 Cr, with margins expanding 120 bps to 13.8% due to product mix optimization and operational efficiencies. While PBT rose 35% YoY to ₹69.2 Cr, PAT declined 7% YoY to ₹50.1 Cr, primarily because the base quarter (Q1 FY26) included a one-time principal tax refund of ₹15 Cr. The Sayakha facility, a key backward integration project, reached ~65% utilization during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved from a period of sharp API price erosion to a stabilizing pricing environment with consistent volume growth.
ஏன் இது முக்கியம்The recovery in margins and the ramp-up of backward integration facilities (Sayakha) are critical for Aarti Drugs to maintain cost competitiveness against Chinese imports and improve operating leverage.
📅 குறுகிய காலம்The stock may react positively to the strong operational EBITDA growth and the stabilization of the pricing environment.
📈 நீண்ட காலம்Structural growth is supported by capacity expansions in Baddi and Sayakha, alongside a strategic shift toward regulated markets and high-growth segments like GLP-1 intermediaries.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility
Chinese oversupply/dumping risks
High therapeutic concentration in Antibiotics (35%)
👀 கவனிக்க வேண்டியவை
Monitor the utilization ramp-up at the Sayakha facility and the execution timeline for the Baddi brownfield expansion, which aims to double oral solid dosage capacity. Investors should also track the management's ability to sustain the 15-16% EBITDA margin target amidst global raw material volatility.
₹10.2 Lakh Penalty Paid as GPCB Revokes Closure Order for Aarti Drugs' Sayakha Plant
The Gujarat Pollution Control Board (GPCB) has revoked a closure direction previously issued for Aarti Drugs' Amines manufacturing plant at Sayakha, Bharuch. The closure order followed an inspection on June 20, 2026, which identified non-compliances with the Water Act. To resume operations, the company paid an interim Environmental Damage Compensation (EDC) of ₹10.20 Lakhs. This facility is a critical component of the company's backward integration strategy, having been commissioned in September 2025.
உச்சம் நம்பிக்கை
என்ன மாறியதுA regulatory threat to the operations of a key manufacturing facility has been resolved through the payment of a penalty and a revocation order from the GPCB.
ஏன் இது முக்கியம்The Sayakha Amines facility is central to Aarti Drugs' strategy to improve cost competitiveness through backward integration; its continued operation is vital for maintaining API margins.
Interim Penalty (EDC): ₹10,20,000Penalty vs Net Worth: 0.007%Inspection Date: ஜூன் 20, 2026Revocation Order Date: ஜூலை 31, 2026
📅 குறுகிய காலம்The removal of the closure threat is a relief for the stock, ensuring no immediate loss of production at a newly commissioned facility.
📈 நீண்ட காலம்While the financial penalty is negligible, the event underscores regulatory risks in the pharma-chemical sector; consistent ESG compliance is necessary to avoid future operational disruptions.
⚠ அபாய எச்சரிக்கைகள்
Regulatory non-compliance
Environmental litigation risk
Potential for higher final compensation beyond the interim amount
👀 கவனிக்க வேண்டியவை
Monitor the company's upcoming quarterly results to ensure the brief disruption at Sayakha did not impact production volumes or the 15-16% EBITDA margin target.
Aarti Drugs Announces Leadership Transition: Rashesh Gogri to Chairman, Adhish Patil to MD
Aarti Drugs has announced a structured leadership transition effective October 1, 2026. Shri Prakash M. Patil will retire as Chairman, MD, and CEO on September 30, 2026, after leading the company since 2014. Shri Rashesh C. Gogri (current MD) will be elevated to Chairman and MD, while Shri Adhish P. Patil (current CFO) will take over as Managing Director. This internal succession aims to maintain continuity as the company pursues its 15% growth target and backward integration projects.
உச்சம் நம்பிக்கை
என்ன மாறியதுA formal succession plan has been activated where the long-standing Chairman/CEO is retiring, and the current MD and CFO are being promoted to lead the company.
ஏன் இது முக்கியம்Internal succession reduces execution risk during a period where the company is heavily investing in backward integration and capacity expansion to improve its 12% operating margins.
Transition Effective Date: அக்டோபர் 1, 2026Total Manufacturing Facilities: 14Rashesh C. Gogri Experience: 27+ yearsAdhish P. Patil CFO Tenure: Since April 2014TTM வருவாய்: Rs 2492 கோடி
📅 குறுகிய காலம்The market is likely to view this as a stable transition given both successors have been with the company for over a decade.
📈 நீண்ட காலம்The transition ensures continuity in the company's strategic shift toward backward integration and high-margin API segments like GLP-1 intermediaries.
⚠ அபாய எச்சரிக்கைகள்
Vacancy in the CFO position following Adhish Patil's promotion
Execution risk during leadership handover
👀 கவனிக்க வேண்டியவை
Investors should monitor the appointment of a new Chief Financial Officer to replace Adhish Patil and track the execution of the Sayakha amines facility and other greenfield projects under the new leadership.
Aarti Drugs Q1 FY27: Net Profit Surges 57% YoY to ₹55.3 Cr; Revenue Up 19%
Aarti Drugs reported a strong YoY performance for Q1 FY27, with consolidated revenue growing 19% to ₹702.78 Cr compared to ₹590.51 Cr in the year-ago quarter. Net profit surged 56.8% YoY to ₹55.26 Cr, maintaining stability sequentially despite a slight 2.4% dip in revenue from the March 2026 quarter. The company recorded a minor exceptional write-off of ₹2.09 Cr related to an administrative building. The results reflect the benefits of backward integration, particularly from the Sayakha amines facility commissioned in late 2025.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarti Drugs has reported its Q1 FY27 financial results, showing significant YoY growth in both top-line and bottom-line figures, alongside a routine exceptional write-off.
ஏன் இது முக்கியம்The strong YoY profit growth indicates that the company's backward integration strategy is effectively offsetting raw material price volatility and domestic demand softness in antibiotics.
Consolidated Revenue (Q1 FY27): ₹702.78 கோடிConsolidated PAT (Q1 FY27): ₹55.26 கோடிYoY Revenue Growth: 19.0%YoY PAT Growth: 56.8%Exceptional Item (CWIP Write-off): ₹2.09 கோடிQ1 வருவாய் vs TTM வருவாய்: 28.2%
📅 குறுகிய காலம்The stock may react positively to the strong YoY profit jump and the fact that sequential earnings remained resilient despite a minor revenue dip.
📈 நீண்ட காலம்Structural growth remains tied to the successful ramp-up of new capacities and the transition toward higher-margin products like GLP-1 intermediaries over the next 5-10 years.
⚠ அபாய எச்சரிக்கைகள்
Soft domestic demand in the antibiotics category
Susceptibility to raw material price fluctuations
Rising finance costs
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to sustain EBITDA margins in the 15-16% range as the Sayakha facility ramps up. Key long-term triggers include the execution of the two Greenfield projects and progress in the GLP-1 anti-diabetic market entry.
GPCB Orders Closure of Aarti Drugs' Saykha Amines Plant; 15-Day Grace Period for Compliance
Aarti Drugs has received a closure directive from the Gujarat Pollution Control Board (GPCB) for its Amines manufacturing facility at Saykha, Bharuch. The order, issued under Section 33A of the Water Act, follows an inspection on June 20, 2026, which identified non-compliance with environmental conditions. The closure is scheduled to take effect 15 days from July 18, 2026, unless the company successfully obtains a revocation. This facility is strategically significant as it was commissioned in September 2025 to drive backward integration and improve EBITDA margins toward the 15-16% target.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Gujarat Pollution Control Board has mandated the shutdown of the company's Saykha Amines plant due to environmental non-compliance observed during a June 2026 inspection.
ஏன் இது முக்கியம்The Saykha facility is a key component of the company's backward integration strategy, intended to reduce raw material costs and boost margins. A prolonged shutdown could delay the realization of these operational efficiencies and impact the TTM revenue of ₹2,492 Cr.
Inspection Date: ஜூன் 20, 2026Notice Receipt Date: ஜூலை 18, 2026Closure Grace Period: 15 நாட்கள்TTM வருவாய்: ₹2,492 கோடிசந்தை மதிப்பு: ₹3,866 கோடி
📅 குறுகிய காலம்The stock may face downward pressure in the coming days as the market reacts to the potential operational disruption at a key facility.
📈 நீண்ட காலம்While the company is taking corrective steps, repeated environmental non-compliance can lead to increased regulatory scrutiny and may delay the company's goal of returning to 15-16% EBITDA margins.
⚠ அபாய எச்சரிக்கைகள்
Regulatory non-compliance
Operational disruption at a key backward integration facility
Potential delay in margin improvement targets
👀 கவனிக்க வேண்டியவை
Investors should monitor the timeline for the company's submission of corrective measures and the subsequent response from GPCB regarding the revocation of the closure order.
Aarti Drugs Q4 FY26: Revenue Grows 6% YoY to ₹721.1 Cr; EBITDA Margins at 13.4%
Aarti Drugs reported a strong sequential recovery in Q4 FY26, with revenue rising 20% quarter-on-quarter to ₹721.1 crores. While PAT declined 12% year-on-year to ₹55.3 crores due to elevated input and energy costs, EBITDA margins stabilized at 13.4%. The company is transitioning from an investment phase to operational scale-up, with the new methylamine plant reaching 40% utilization and targeting 70% within a year. Notably, the contribution from regulated markets within exports increased to 73%, reflecting a shift toward higher-value products.
முக்கிய அம்சங்கள்
Q4 FY26 revenue stood at ₹721.1 crores, up 6% YoY and 20% QoQ.Formulation segment revenue surged 41% YoY to ₹91.3 crores, driven by export momentum.Methylamine plant at Sayakha achieved 40% utilization in Q4, with a target of 55-60% for Q1 FY27.Regulated market contribution to exports improved to 73% in FY26 from 66% in FY25.Company targets 8-10% volume growth for FY27, supported by greenfield expansions and backward integration.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful ramp-up of the Sayakha facility and the potential margin expansion from backward integration. The increasing share of regulated markets and formulations suggests a structural improvement in the business mix despite short-term pricing volatility.
Aarti Drugs Q4 FY26: Revenue Up 6% to ₹721 Cr; PAT Declines 12% YoY Amid Margin Pressure
Aarti Drugs reported a steady 7% YoY revenue growth for FY26, reaching ₹2,568 crore, though Q4 FY26 PAT declined 12% YoY to ₹55.3 crore due to start-up losses at new facilities and domestic antibiotic market weakness. However, the company showed a strong sequential recovery in Q4, with EBITDA rising 72% QoQ and margins expanding by 410 bps to 13.4%. A key operational milestone was achieved at the Sayakha facility, reaching a run-rate of ~1,000 tonnes per month. The business mix is shifting favorably, with regulated market contribution rising to 73% and exports increasing to 38% of total revenue.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 6% YoY to ₹721.1 crore, showing a strong 20% sequential recovery from Q3 FY26.Full-year FY26 PAT increased 16% to ₹194.9 crore, despite pricing pressures in the API segment during the first half.Sayakha facility reached a milestone production run-rate of ~1,000 tonnes per month in March 2026.Contribution from regulated markets improved significantly to 73% in FY26 from 66% in FY25.Specialty Chemicals and Formulations segments grew robustly by 37% and 33% YoY respectively.
👀 கவனிக்க வேண்டியவை
Investors should focus on the margin trajectory in FY27 as the Sayakha facility stabilizes and backward integration benefits materialize. While API pricing volatility remains a factor, the increasing share of regulated markets and exports provides a positive long-term outlook for earnings stability.
Aarti Drugs Reports FY26 Consolidated PAT Growth of 16% to ₹194.9 Crore
Aarti Drugs Limited delivered a steady financial performance for the fiscal year ended March 31, 2026, with consolidated revenue rising 9.9% year-on-year to ₹2,387 crore. The company's consolidated net profit for the full year grew by 16% to ₹194.9 crore, up from ₹168.1 crore in FY25. For the final quarter (Q4 FY26), revenue stood at ₹720.3 crore with a profit of ₹55.3 crore. Alongside the results, the board re-appointed its cost and internal auditors and expanded its Risk Management Committee.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 grew 9.9% YoY to ₹2,38,703 lakhs compared to ₹2,17,177 lakhs in FY25.Full-year Consolidated Net Profit increased by 16% to ₹19,494 lakhs from ₹16,810 lakhs.Basic EPS for the full year improved to ₹21.36 from ₹18.35 in the previous fiscal.Q4 FY26 Consolidated Revenue rose 6.4% YoY to ₹72,030 lakhs.Total Consolidated Assets increased to ₹2,81,526 lakhs as of March 31, 2026, from ₹2,57,468 lakhs a year ago.
👀 கவனிக்க வேண்டியவை
Investors should view the consistent double-digit profit growth and steady revenue expansion as a sign of operational stability. The stock remains a watch for those looking for steady growth in the pharmaceutical bulk drugs and chemicals space.
Aarti Drugs Q4 FY26 Net Profit Jumps 36% to ₹55.26 Cr; Full Year EPS Rises to ₹21.36
Aarti Drugs Limited reported a robust 36% year-on-year growth in consolidated net profit for Q4 FY26, reaching ₹55.26 crore. Consolidated revenue for the quarter rose 6.4% to ₹720.30 crore compared to the previous year. For the full financial year 2026, the company posted a net profit of ₹194.94 crore on a revenue of ₹2,387.03 crore, reflecting steady operational growth. The board also confirmed the re-appointment of internal and cost auditors and updated the Risk Management Committee.
முக்கிய அம்சங்கள்
Consolidated Q4 net profit increased by 36.3% YoY to ₹55.26 crore from ₹40.54 crore.Full-year FY26 consolidated revenue grew 8.9% to ₹2,387.03 crore compared to ₹2,191.62 crore in FY25.Annual Earnings Per Share (EPS) improved to ₹21.36 in FY26 from ₹18.35 in the previous fiscal.Consolidated Total Equity rose to ₹1,549.23 crore as of March 31, 2026, up from ₹1,369.34 crore in 2025.Re-appointed M/s Raman S. Shah & Co. as Internal Auditors for a three-year term starting April 2026.
👀 கவனிக்க வேண்டியவை
The company demonstrates strong bottom-line growth and improving profitability margins; investors should maintain a positive outlook while monitoring raw material cost trends. Existing shareholders may hold as the steady EPS growth suggests healthy business fundamentals.
Aarti Drugs Faces Supreme Court Challenge from GST Dept Over ₹230.70 Cr Tax Dispute
The GST Department has filed a Special Leave Petition (SLP) in the Supreme Court challenging a Bombay High Court order that was previously in favor of Aarti Drugs. The dispute originates from a Show Cause Notice for FY 2017-18 to FY 2021-22 involving an IGST demand of ₹230.70 Crores. Although the High Court had earlier set aside the CGST authority's demand of ₹20.72 Crores plus penalties, the matter is now sub-judice at the highest court. This move reintroduces financial uncertainty regarding potential tax liabilities and penalties.
முக்கிய அம்சங்கள்
GST Department files SLP in Supreme Court against the Bombay High Court's favorable order for the company.Original dispute involves a total proposed IGST demand of ₹230.70 Crores for the period FY 2017-22.Previous CGST order had confirmed a demand of ₹20.72 Crores and an equivalent penalty of ₹20.72 Crores.The Bombay High Court had previously set aside the entire demand before this Supreme Court challenge.Company states it is currently difficult to assess the exact financial impact as the matter is sub-judice.
👀 கவனிக்க வேண்டியவை
Investors should monitor the Supreme Court proceedings closely as a reversal of the High Court order could lead to significant cash outflows. No immediate action is required, but the legal risk premium on the stock may increase due to the size of the original claim.
Aarti Drugs to Invest ₹10 Crore in Subsidiary Pinnacle Life Science for Expansion
Aarti Drugs Limited has approved an investment of ₹10 crore in its wholly-owned subsidiary, Pinnacle Life Science Private Limited, through a rights issue. The capital infusion is specifically intended to finance Pinnacle's expansion and capital expenditure plans, alongside general corporate purposes. Pinnacle is a key formulations player for the group, exporting to over 30 countries, though its turnover saw a decline to ₹253.92 crore in FY25 from ₹314.66 crore in FY24. This investment signals the parent company's commitment to strengthening its formulations business segment.
முக்கிய அம்சங்கள்
Investment of ₹10 crore via subscription to 78,125 equity shares at a price of ₹1,280 per share (including premium).Pinnacle Life Science reported a turnover of ₹253.92 crore for FY 2024-25.Funds will be utilized for financing expansion/capex plans and general corporate purposes.Pinnacle operates in high-growth segments including oncology, cardiovascular, anti-infectives, and diabetics.The share allotment is expected to be completed on or before March 20, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic move to bolster the formulations subsidiary, though they should monitor if this capex helps reverse the recent decline in Pinnacle's annual turnover.
Aarti Drugs Q3 FY26: PAT Surges 58% to ₹40.5 Cr Despite EBITDA Margin Pressure
Aarti Drugs reported a mixed performance for Q3 FY26, with consolidated revenue growing 8% YoY to ₹602.9 crores and PAT surging 58% to ₹40.5 crores. However, EBITDA declined 10% YoY to ₹56.3 crores with margins contracting to 9.3% due to weak antibiotic demand, supply chain disruptions from China, and one-time plant shutdowns for refurbishment. The formulations segment was a bright spot, growing 58% YoY, driven by strong export demand. Management expects significant margin improvement as the new Sayakha facility ramps up from 30% to 50% utilization by April 2026.
முக்கிய அம்சங்கள்
Consolidated revenue increased 8% YoY to ₹602.9 crores, while PAT rose 58% to ₹40.5 crores.Formulations segment revenue grew 58% YoY to ₹76.6 crores, with exports accounting for 67% of segment sales.The Sayakha greenfield facility achieved 30% utilization in its first quarter, targeting 50% by April 2026.Operational headwinds including plant shutdowns and ramp-up costs impacted PBT by approximately ₹14-15 crores.First oncology product commercialization is scheduled for Q4 FY26, with oncology expected to contribute 40% of formulation revenue in 3 years.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful ramp-up of the Sayakha facility and the commercialization of the oncology pipeline in Q4 as key triggers for margin recovery. While short-term margins are under pressure, the backward integration strategy is expected to add ₹50 crores to annual EBITDA at full scale.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
